Elastrin Therapeutics Inc.

Restoring the Elastic of Life

"This new delivery system may prove especially useful for patients with cardiovascular disease...Fixing the vessels may ultimately reverse the course of the disease."

Dr. Francis Collins
Director, US National Institute of Health

About Us

Elastrin Therapeutics is a biotech startup with technologies to restore hardened and damaged arteries & tissue by targeting the elastic fiber that makes them work.

Our Mission

Improve quality of life by restoring damaged hardened tissue to healthy resilience.

Our Special Achievement

Proof of principle reversing hardening of arteries and inflammatory tissue damage in arterial and lung disease models. The potential is described at top of this page from an analysis by U.S.. National Institutes of Health Director Dr. Francis Collins.

Learn about our Heritage

Publications

Learn more

Our Therapeutic Targets

Hardening Of Arteries

Calcified Heart Valves

Diabetes

COPD

Our Technology

Elastin degradation is a leading contributor to heart disease, aneurysms and COPD. Learn more

Our team built a proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries.

The platform significantly improves the efficacy of drugs and eliminates side-effects by combining particle design with elastin targeting.

Antibody for elastin targeting

Special configuration to keep out of cells

Drug release over ~10 days

Image: Naren Vyavahare

Drug cargo

Meet the Team

Our interdisciplinary team has extensive track records in antibody development, bioengineering, molecular medicine, medical engineering, and environmental health as well as regulatory approvals, and finance & management. Our team members have a proven track record in entrepreneurship and successful startups.

Meet our Advisors

Meet the Founders